Literature DB >> 31812526

Multi-city study on air pollution and hospital outpatient visits for asthma in China.

Peng Lu1, Yongming Zhang2, Jiangtao Lin3, Guoxin Xia4, Wenyi Zhang5, Luke D Knibbs6, Geoffrey G Morgan7, Bin Jalaludin8, Guy Marks9, Michael Abramson10, Shanshan Li11, Yuming Guo12.   

Abstract

BACKGROUND: The proportion of asthma patients with mild to moderate exacerbations is far greater than the number who experience episodes that are severe enough to require emergency room visits or hospital admission. However the routinely collected data from hospitals is absent in the past.
OBJECTIVE: To evaluate associations between short-term exposures to air pollutants and hospital outpatient visits for asthma in China.
METHODS: We obtained data for 143,057 asthma outpatient visits from the largest hospitals in 17 Chinese cities, between Jan 01 2013 and Dec 31 2015. We used daily concentrations of air pollutants measured by the China National Environmental Monitoring Centre. We used a time-stratified case-crossover design, and fitted conditional logistic regression models to determine the associations.
RESULTS: Particulate matter ≤10μm in diameter (PM10) and nitrogen dioxide (NO2) were associated with increased risks of hospital outpatient visits for asthma on the same day, while the effects were delayed for particulate matter ≤2.5μm in diameter (PM2.5) and sulphur dioxide (SO2). For the cumulative effect model at lag05 days, 10 μg/m3 increase in air pollutants concentrations were correlated with hospital outpatient visits for asthma with odds ratios (ORs) and 95% confidence intervals 1.004 (1.000-1.008) for PM2.5, 1.005 (1.002-1.008) for PM10, 1.030 (1.021-1.040) for NO2, and 1.015 (1.008-1.021) for SO2. Almost one in nine (10.9%; 7.7, 13.9%) hospital outpatient visits for asthma were attributable to NO2.
CONCLUSION: Short-term exposures to PM2.5, PM10, NO2 and SO2 were associated with hospital outpatient visits for asthma in China.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asthma exacerbation; China; air pollution; hospital outpatient visits

Mesh:

Substances:

Year:  2019        PMID: 31812526     DOI: 10.1016/j.envpol.2019.113638

Source DB:  PubMed          Journal:  Environ Pollut        ISSN: 0269-7491            Impact factor:   8.071


  6 in total

1.  Ambient Air Pollution and Risk of Admission Due to Asthma in the Three Largest Urban Agglomerations in Poland: A Time-Stratified, Case-Crossover Study.

Authors:  Piotr Dąbrowiecki; Andrzej Chciałowski; Agata Dąbrowiecka; Artur Badyda
Journal:  Int J Environ Res Public Health       Date:  2022-05-14       Impact factor: 4.614

2.  Impact of a pollution breach at a coke oven factory on asthma control in nearby vulnerable adults.

Authors:  Brandy M Byrwa-Hill; Albert A Presto; Sally Wenzel; James P Fabisiak
Journal:  J Allergy Clin Immunol       Date:  2021-04-21       Impact factor: 14.290

3.  Effects of particulate matter on hospital admissions for respiratory diseases: an ecological study based on 12.5 years of time series data in Shanghai.

Authors:  Wenjia Peng; Hao Li; Li Peng; Ying Wang; Weibing Wang
Journal:  Environ Health       Date:  2022-01-13       Impact factor: 5.984

4.  Individual exposure to ambient PM2.5 and hospital admissions for COPD in 110 hospitals: a case-crossover study in Guangzhou, China.

Authors:  Jie-Qi Jin; Dong Han; Qi Tian; Zhao-Yue Chen; Yun-Shao Ye; Qiao-Xuan Lin; Chun-Quan Ou; Li Li
Journal:  Environ Sci Pollut Res Int       Date:  2021-09-21       Impact factor: 4.223

5.  Exposure Response Relationship of Acute Effects of Air Pollution on Respiratory Diseases - China, 2013-2018.

Authors:  Hongtao Niu; Tao Yu; Xuexin Li; Hanna Wu; Meilin Yan; Ruirui Duan; Ting Yang
Journal:  China CDC Wkly       Date:  2021-11-05

6.  Air Quality Response in China Linked to the 2019 Novel Coronavirus (COVID-19) Lockdown.

Authors:  K Miyazaki; K Bowman; T Sekiya; Z Jiang; X Chen; H Eskes; M Ru; Y Zhang; D Shindell
Journal:  Geophys Res Lett       Date:  2020-10-06       Impact factor: 4.720

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.